(Reuters) – Eli Lilly (NYSE:LLY) expects to start selling its weight-loss drug in Hong Kong as early as the end of this year, Bloomberg News reported on Sunday.
The company has received the Hong Kong government approval to sell its tirzepatide injections — branded as Mounjaro — in a device called Kwikpen for both long-term weight management and type 2 diabetes, Eli Lilly told Bloomberg in a statement.
This post appeared first on investing.com